Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
HIV & AIDS
Which patients with NNRTI resistance mutations who wish to simplify their HIV antiretroviral regimens do you consider switching to cabotegravir/rilpivirine?
Related Questions
How do you use CD4% in clinical practice in management of patients living with HIV?
Do you favor a certain NRTI to pair with dolutegravir and lamivudine in persons with HIV to minimize the risk of resistance to dolutegravir?
In what situations would you use "direct-to-inject" ART, such as Cabenuva, without an oral lead-in?
What are your top takeaways from ID Week 2024?
What is your approach when cryptococcus serum or CSF antigen titers do not change despite treatment in HIV-positive patients with cryptococcal meningitis or invasive disease, but there is clinical improvement and cultures remain negative?
Do you have any concerns about using long-acting cabotegravir/rilpivirine in obese patients with HIV?
Do you recommend to continue acyclovir to prevent HSV infection in an HIV patient with CD4 count more than 200 and with high viral load?
How do you approach management for patient's with HIV on ART with persistent low level viremia but no new resistance mutations identified?
Would you consider using long-acting injectable cabotegravir/rilpivirine for pregnant women with HIV?
Would you recommend switching from an integrase strand transfer inhibitor-based regimen to a different antiretroviral regimen, or would you instead add weight loss medications for a person with HIV experiencing weight gain that has not improved with lifestyle changes?
